Cannara Biotech Financials

LOVE Stock  CAD 0.68  0.01  1.49%   
We suggest to use Cannara Biotech analysis to find out if markets are presently mispricing the company. We were able to interpolate and analyze data for thirty available fundamental indicators for Cannara Biotech, which can be compared to its peers. The stock experiences a large bullish trend. Check odds of Cannara Biotech to be traded at C$0.748 in 90 days. Key indicators impacting Cannara Biotech's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.560.66
Fairly Down
Slightly volatile
Current Ratio5.282.81
Way Up
Slightly volatile
  
Understanding current and past Cannara Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cannara Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Cannara Biotech's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Cannara Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cannara Biotech. Check Cannara Biotech's Beneish M Score to see the likelihood of Cannara Biotech's management manipulating its earnings.

Cannara Biotech Stock Summary

Cannara Biotech competes with Lion Electric, and Rubicon Organics. Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. The company was incorporated in 2017 and is headquartered in Montreal, Canada. CANNARA BIOTECH is traded on Commodity Exchange in Exotistan.
Foreign Associate
  USA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentCanada Stock View All
ExchangeTSX Venture Exchange
ISINCA13765U1012
Business Address333 Decarie Blvd,
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitecannara.ca
Phone514 543 4200
CurrencyCAD - Canadian Dollar
You should never invest in Cannara Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cannara Stock, because this is throwing your money away. Analyzing the key information contained in Cannara Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Cannara Biotech Key Financial Ratios

There are many critical financial ratios that Cannara Biotech's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cannara Biotech reports annually and quarterly.

Cannara Biotech Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets54.9M92.0M125.6M141.5M162.8M93.7M
Net Tangible Assets46.9M38.2M64.1M66.7M76.7M50.7M
Retained Earnings(27.1M)(28.6M)(26.3M)(19.3M)(17.4M)(18.3M)
Accounts Payable2.8M6.2M8.8M13.9M16.0M16.8M
Cash7.8M8.2M12.1M4.3M3.8M3.7M
Other Assets733.8K514.2K1.0M1.2M1.1M808.0K
Long Term Debt12.0M20.2M46.2M39.6M45.6M26.2M
Net Receivables26.4K2.8M8.5M10.6M12.2M12.8M
Total Liab16.5M27.9M58.9M61.8M71.0M36.2M
Net Invested Capital50.6M84.6M114.9M125.4M144.2M84.8M
Total Current Assets10.5M19.2M41.0M51.7M59.5M30.0M
Capital Stock58.4M83.2M83.3M88.8M102.1M70.5M
Net Working Capital7.1M12.4M29.1M30.5M35.1M20.9M
Common Stock54.9M58.4M83.2M83.3M95.8M65.4M
Inventory2.2M7.4M19.0M33.8M38.8M40.8M

Cannara Biotech Key Income Statement Accounts

201920202021202220232024 (projected)
Net Interest Income(1.1M)(1.7M)(3.2M)(5.0M)(4.5M)(4.3M)
Interest Income265.8K52.8K92.7K239.5K215.6K181.0K
Interest Expense1.3M1.6M1.9M3.9M4.5M4.7M
Total Revenue2.5M16.3M35.8M57.3M65.8M69.1M
Gross Profit1.1M9.6M17.3M27.2M31.3M32.9M
Operating Income(11.9M)299.2K5.0M12.0M13.8M14.5M
Ebit(9.9M)(12.0M)52.6K4.8M5.5M5.8M
Ebitda(10.9M)(9.2M)3.1M8.1M9.4M9.8M
Cost Of Revenue1.3M6.7M18.5M30.0M34.5M36.3M
Income Before Tax(13.1M)(1.5M)2.3M6.9M8.0M8.4M
Net Income(12.5M)(1.5M)2.3M6.9M8.0M8.4M

Cannara Biotech Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory(2.5M)(3.4M)(8.2M)(8.3M)(7.5M)(7.1M)
Investments(8.6M)(30.8M)(15.3M)(9.5M)(10.9M)(11.4M)
Change In Cash(18.7M)388.1K4.0M(7.8M)(7.0M)(6.6M)
Net Borrowings(235.5K)(562.7K)10.1M27.6M31.7M33.3M
Free Cash Flow(18.1M)(33.2M)(21.5M)(4.4M)(5.1M)(5.4M)
Depreciation2.4M2.9M3.9M4.9M5.7M6.0M
Other Non Cash Items1.1M(169.2K)(659.0K)(2.2M)(2.0M)(1.9M)
Capital Expenditures9.2M30.6M15.1M9.9M8.9M15.4M
Net Income(12.5M)(1.5M)2.3M6.9M8.0M8.4M
End Period Cash Flow7.8M8.2M12.1M4.3M3.8M3.7M
Change To Netincome4.1M1.7M189.3K(937.6K)(843.9K)(801.7K)

Cannara Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cannara Biotech's current stock value. Our valuation model uses many indicators to compare Cannara Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cannara Biotech competition to find correlations between indicators driving Cannara Biotech's intrinsic value. More Info.
Cannara Biotech is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about  0.56  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Cannara Biotech is roughly  1.79 . At this time, Cannara Biotech's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cannara Biotech's earnings, one of the primary drivers of an investment's value.

Cannara Biotech Systematic Risk

Cannara Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cannara Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Cannara Biotech correlated with the market. If Beta is less than 0 Cannara Biotech generally moves in the opposite direction as compared to the market. If Cannara Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cannara Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cannara Biotech is generally in the same direction as the market. If Beta > 1 Cannara Biotech moves generally in the same direction as, but more than the movement of the benchmark.

Cannara Biotech Total Assets Over Time

Today, most investors in Cannara Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cannara Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cannara Biotech growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0717

At this time, Cannara Biotech's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Cannara Biotech November 25, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Cannara Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cannara Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cannara Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Cannara Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cannara Biotech's daily price indicators and compare them against related drivers.

Additional Tools for Cannara Stock Analysis

When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.